'24e-'26e EBITDA cut by 14-1% Near-term margin pressure driven by business transformation '24e EV/EB...
Redeye makes minor revisions based on the Q1 report.
Redeyes’ long-term view of Dignitana is intact despite the flat sales progression.
Calliditas delivers a positive surprise in patient enrolment (18% above our expectations) and new su...
23% ARR growth: strong new sales, with churn and uplift weaker.
Redeye comments on Tango Therapeutics' discontinuation of the USP1 programme (TNG348), which does no...
STENOCARE announced on May 23rd that the company’s premium product, the Astrum oil, is ready for lau...
This morning ChromoGenics has received an offer from Färna Invest of SEK10 in cash per share.
Starkt kvartal över förväntan Under kv1 2024 levererade Fable Media en nettoomsättning i linje med...
Redeye comments on the much-awaited news from Tessin, which has signed a letter of intent with a Eur...
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Redeye gives its initial comments on the news flow from Fragbite Group earlier this morning, where F...
Cell impact visade som väntat fortsatt en rörelseförlust under kvartalet och negativa kassaflöden.
Redeye saw a sales development that was stronger than expected.
